A sponsor-focused guide to clinical trials in Poland; covering patient access, EU-aligned regulation, leading sites, therapeutic strengths, and why Poland remains one of Central Europe's most important research markets.
Poland is one of the most important destinations for clinical trials in Central and Eastern Europe. With a population of approximately 38 million people, EU-aligned regulation, a large hospital network, and deep investigator experience, Poland gives sponsors the rare combination of scale, quality, and operational efficiency.
An EU member since 2004, Poland has built one of the most robust economies in Central and Eastern Europe, driven by manufacturing, technology, and pharmaceuticals. Its healthcare system operates on a universal insurance model administered by the National Health Fund (NFZ), with a growing private sector and an increasingly modern digital health infrastructure including nationwide electronic medical records, e-prescriptions, and e-referrals.
Poland's pharmaceutical market; valued at approximately USD 10 billion; is one of the largest in the region, and its clinical research sector has grown in tandem, now accounting for around 21% of all clinical trials conducted in Central and Eastern Europe.
Poland's population of 38 million is predominantly ethnically Polish, with a median age of approximately 40 years. The largest demographic cohort is the working-age group (15–64 years), which represents around 63% of the total population. Over 60% of Poles live in urban areas, concentrated in Warsaw, Kraków, Łódź, Wrocław, Poznań, and Gdańsk; cities that also host the country's densest clusters of clinical trial sites.
The country has a meaningful aging demographic trend, driving growing incidence of chronic conditions across oncology, cardiology, and neurology; precisely the therapeutic areas where Poland's trial activity is strongest. Importantly, Poland offers access to large, relatively treatment-naïve patient populations in several therapeutic areas compared to Western Europe, where prior exposure to competing studies and experimental agents is higher.
Scale advantage: Poland can facilitate an average of 40,000 patients per year taking part in clinical trials; a volume that rivals much larger Western European markets and gives sponsors meaningful enrollment velocity at competitive cost.
Poland ranked 9th in the global commercial clinical trials market in 2024, with a 2.68% market share. International sponsors account for 73% of all ongoing trials; a strong signal of how deeply Poland is integrated into global research networks. Its combination of scale, regulatory maturity, and cost efficiency makes it one of Europe's most compelling research destinations.
Regulatory approval takes 60 days via the EU CTIS system. Ethics committee and competent authority reviews run in parallel, enabling one of the faster startup timelines in the EU.
Clinical trial costs in Poland average 30% below US levels, with lower investigator fees, operational overhead, and patient recruitment costs; without sacrificing data quality or GCP compliance.
A population of 38 million with 40,000 trial participants per year, large naïve patient pools in oncology, cardiology, and neurology, and high investigator motivation to enroll.
Over 800 hospitals and 16,600 outpatient facilities. The Polish Clinical Trials Network (est. 2021) links 23 specialized Clinical Trial Support Centres nationwide, standardizing quality and accelerating startup.
Since 2022, Poland has initiated over 1,307 clinical trials. Oncology dominates; reflecting the strength of the National Oncology Network and the country's dedicated cancer research infrastructure. The majority of trials are Phase III (34%), with a strong Phase II pipeline. Poland holds a particularly notable position in hematology and CAR-T cell therapy research, with several centers among the first in Europe to adopt novel immunotherapy approaches.
Poland's leading investigational sites are distributed across its major cities, with Warsaw, Kraków, Poznań, Wrocław, and Gdańsk serving as the primary research hubs. Many of these institutions are members of the Polish Clinical Trials Network and have dedicated Clinical Trial Support Centres (CTSCs) on-site.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Maria Skłodowska-Curie National Research Institute of Oncology | Warsaw | Founded 1932; Poland's leading cancer center; manages 650+ active clinical trials including 80 early-phase; ESMO-designated |
| 02 | National Oncology Institute; Gliwice Branch | Gliwice | 45,500 patients annually; 120+ trials in last 15 years; OncoCTSC designation; leader in EORTC and PALG trials |
| 03 | Cardinal Stefan Wyszyński Institute of Cardiology | Warsaw | National cardiology reference center; CTSC member; cardiovascular Phase II–IV trials |
| 04 | Medical University of Warsaw; University Clinical Hospital | Warsaw | Major academic hospital; broad therapeutic area coverage; hematology, neurology, oncology, and internal medicine trials |
| 05 | Jagiellonian University Hospital (UCJ) | Kraków | One of Poland's oldest and most prestigious academic medical centers; active across oncology, cardiology, and neurology |
| 06 | Poznan University of Medical Sciences; Clinical Hospital | Poznań | Early-phase center; 16 beds; hematology, oncology, cardiology; first in Poland to deploy CAR-T cell therapy |
| 07 | Wrocław Medical University; University Clinical Hospital | Wrocław | CTSC member; cardiology, hematology, oncology, and neurosurgery; 1,078 hospital beds, 100,000+ patients/year |
| 08 | National Institute of Geriatrics, Rheumatology & Rehabilitation | Warsaw | CTSC member; specializes in rheumatology (adult & pediatric), immunology, dermatology, orthopedics, and neurology |
| 09 | MTZ Clinical Research (Pratia Network) | Warsaw | Founded 2002; Phase I early-development and bioequivalence specialist; part of Pratia/Neuca Group European network |
| 10 | Pomeranian Medical University Clinical Hospitals | Szczecin | Two clinical campuses; 350,000+ outpatient consultations/year; broad multi-specialty trial capability |
| 11 | Medical University of Łódź; University Hospital | Łódź | Active across oncology, cardiology, and biostatistics; home to key MRA-affiliated researchers |
| 12 | University Clinical Centre; Gdańsk Medical University | Gdańsk | Northern Poland's primary academic research hospital; active in oncology, cardiology, and transplantation |
| 13 | National Medical Institute; Ministry of Internal Affairs | Warsaw | CTSC member; cardiology and heart failure focus; President-elect of Heart Failure Association of Polish Society of Cardiology based here |
| 14 | Esploro Clinical Research Center (Centrum Bocian Network) | Warsaw / National | Dedicated research sites in Warsaw, Poznań, Katowice, Szczecin, Białystok; gynecology, endocrinology, andrology Phase II–III |
| 15 | Selvita Drug Discovery & Development (Kraków campus) | Kraków | Integrated drug discovery and early-phase clinical support; oncology, inflammation, respiratory, and neuroscience specialisms |
Founded 1932; Poland's leading cancer center; manages 650+ active clinical trials including 80 early-phase; ESMO-designated
45,500 patients annually; 120+ trials in last 15 years; OncoCTSC designation; leader in EORTC and PALG trials
National cardiology reference center; CTSC member; cardiovascular Phase II–IV trials
Major academic hospital; broad therapeutic area coverage; hematology, neurology, oncology, and internal medicine trials
One of Poland's oldest and most prestigious academic medical centers; active across oncology, cardiology, and neurology
Early-phase center; 16 beds; hematology, oncology, cardiology; first in Poland to deploy CAR-T cell therapy
CTSC member; cardiology, hematology, oncology, and neurosurgery; 1,078 hospital beds, 100,000+ patients/year
CTSC member; specializes in rheumatology (adult & pediatric), immunology, dermatology, orthopedics, and neurology
Founded 2002; Phase I early-development and bioequivalence specialist; part of Pratia/Neuca Group European network
Two clinical campuses; 350,000+ outpatient consultations/year; broad multi-specialty trial capability
Active across oncology, cardiology, and biostatistics; home to key MRA-affiliated researchers
Northern Poland's primary academic research hospital; active in oncology, cardiology, and transplantation
CTSC member; cardiology and heart failure focus; President-elect of Heart Failure Association of Polish Society of Cardiology based here
Dedicated research sites in Warsaw, Poznań, Katowice, Szczecin, Białystok; gynecology, endocrinology, andrology Phase II–III
Integrated drug discovery and early-phase clinical support; oncology, inflammation, respiratory, and neuroscience specialisms
These are the primary regulatory, academic, and industry bodies shaping Poland's clinical research ecosystem.
National competent authority; manages clinical trial authorization via CTIS with a 60-day approval timeline
Government body funding and coordinating clinical research; leads the Polish Clinical Trials Network and Clinical Trial Support Centres (CTSCs) programme
Oversees healthcare policy, the National Oncology Network, and the National Cardiology Network that channel patients into clinical research pathways
Universal insurance administrator; manages reimbursement and healthcare contracting for institutions running publicly-funded trials
Poland's largest and most internationally connected medical university; primary investigator pipeline for Warsaw-based trials
One of Europe's oldest universities; strong oncology, cardiology, and rare disease research output
Active CTSC member with early-phase capability; 100,000+ patients across two campuses annually
Industry association promoting GCP standards, investigator training, and regulatory harmonization across Polish trial sites
Regional CRO with strong Polish presence; Phase I–IV expertise; oncology, cardiology, and dermatology focus
CEE-specialist CRO; full-service from submission through close-out; deep regulatory expertise in Polish CTIS processes
Warsaw-based Phase I specialist since 2002; part of Pratia's pan-European site network; bioequivalence and early-phase focus
Global mid-size CRO; oncology, neurology, and immunology focus; strong Phase I–IV execution capability in Poland
Full-service global CRO with Warsaw operations; CNS, cardiovascular, and oncology specialisms
Integrated drug discovery and development CRO; Kraków-based; GMP/GLP-certified; oncology, inflammation, and neuroscience
For sponsors evaluating clinical trials in Poland, the opportunity is defined by the country's regulatory pathway, investigator depth, patient access, and fit within a wider regional clinical research strategy. This profile is designed to support faster country feasibility, smarter site selection, and more informed clinical trial planning through Kitsa.
Poland is not an emerging market; it is an established, mature, and deeply integrated player in global clinical research, ranked 9th in the world. For sponsors, it offers a rare combination: a large, motivated patient population of 38 million, EU-aligned regulation with a 60-day approval window, trial costs averaging 30% below the US, and a national infrastructure purposefully built to attract and support commercial research. Whether you're running a Phase I first-in-human or a global Phase III oncology study, Poland belongs on your site selection shortlist.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.